Adicet Bio reported early efficacy and safety data for its donor-derived, allogeneic CAR-T approach in lupus nephritis, with half of evaluable patients achieving a complete kidney response at one year. The company said 54% met a commonly used remission threshold and that responders were able to stop immunosuppressive drugs. Adicet reported no serious cytokine release syndrome cases and no neurological side effects in its evaluable cohort, addressing two key safety concerns that have slowed progress for some autologous and individualized CAR-T programs in autoimmune disease. The company also said infections occurred in more than half of patients, with about 8% experiencing grade 3 or higher severity. The update supports Adicet’s plan to initiate a pivotal lupus study in the fourth quarter. The program’s “off-the-shelf” gamma delta CAR-T design is intended to reduce manufacturing delays and lower complexity versus personalized cell therapies.